Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Marker Therapeutics Inc (MRKR)
Marker Therapeutics Inc (MRKR) News

MRKR

Marker Therapeutics (MRKR)

Marker Therapeutics Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MRKR

<< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >>

Date	Time	Source	Headline	Symbol	Company
07/05/2023	4:22PM	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MRKR	Marker Therapeutics Inc
07/03/2023	4:05PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
06/30/2023	4:05PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
06/26/2023	7:15AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
06/26/2023	7:00AM	GlobeNewswire Inc.	Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration	NASDAQ:MRKR	Marker Therapeutics Inc
06/12/2023	7:10AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
06/12/2023	7:00AM	GlobeNewswire Inc.	Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial	NASDAQ:MRKR	Marker Therapeutics Inc
06/09/2023	4:06PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
05/31/2023	6:45AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
05/31/2023	6:30AM	GlobeNewswire Inc.	Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells	NASDAQ:MRKR	Marker Therapeutics Inc
05/15/2023	4:16PM	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:MRKR	Marker Therapeutics Inc
05/11/2023	6:11PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MRKR	Marker Therapeutics Inc
05/08/2023	7:45AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
05/08/2023	7:30AM	GlobeNewswire Inc.	Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer	NASDAQ:MRKR	Marker Therapeutics Inc
05/01/2023	7:37AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
05/01/2023	7:30AM	GlobeNewswire Inc.	Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™	NASDAQ:MRKR	Marker Therapeutics Inc
04/28/2023	4:12PM	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:MRKR	Marker Therapeutics Inc
04/28/2023	4:12PM	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:MRKR	Marker Therapeutics Inc
03/22/2023	8:21AM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:MRKR	Marker Therapeutics Inc
03/22/2023	8:19AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
03/22/2023	8:10AM	GlobeNewswire Inc.	Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results	NASDAQ:MRKR	Marker Therapeutics Inc
03/01/2023	4:53PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MRKR	Marker Therapeutics Inc
03/01/2023	4:52PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MRKR	Marker Therapeutics Inc
03/01/2023	4:52PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MRKR	Marker Therapeutics Inc
03/01/2023	4:50PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MRKR	Marker Therapeutics Inc
01/26/2023	4:17PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MRKR	Marker Therapeutics Inc
01/03/2023	9:01AM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:MRKR	Marker Therapeutics Inc
01/03/2023	6:05AM	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:MRKR	Marker Therapeutics Inc
12/23/2022	9:01AM	Edgar (US Regulatory)	Securities Registration Statement (s-1)	NASDAQ:MRKR	Marker Therapeutics Inc
12/13/2022	7:00AM	GlobeNewswire Inc.	Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million	NASDAQ:MRKR	Marker Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:MRKR

<< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >>

Canopus Biopharma (PK)

Gold and GemStone Mining (PK)

Marketing Worldwide (PK)

Virexit Technologies (PK)

Bell Buckle (PK)

Ubiquitech Software (PK)

Brookmount Explorations (PK)

NioCorp Developments

Fannie Mae (QB)

Anavex Life Sciences

Decentral Life (PK)

Seven Arts Entertainment (PK)

Delayed Upgrade Clock